-transparent.png){kind=logo}
In a clinically controlled double-blind study it was demonstrated that tri-(hydroxyethyl)-rutin is not capable of significantly improving blood viscosity or one of its constituent factors. On the basis of data from 58 patients, none of whom was under 43 years old, it was possible to show that the substance tested has no favorable influence on plasma viscosity, erythrocyte deformability and aggregation, or on the concentration of plasma proteins which promote aggregation. Thus, in the very group of patients for whom an improvement in blood flow properties by means of oral administration of tri-(hydroxyethyl)rutin had been hoped for, no therapeutic effect could be demonstrated.
G Gallasch, and
C Dörfer, and
T Schmitt, and
A Stage
April 1974,
Arzneimittel-Forschung,
G Gallasch, and
C Dörfer, and
T Schmitt, and
A Stage
January 2005,
Arzneimittel-Forschung,
G Gallasch, and
C Dörfer, and
T Schmitt, and
A Stage
September 1985,
Klinische Monatsblatter fur Augenheilkunde,
G Gallasch, and
C Dörfer, and
T Schmitt, and
A Stage
January 1974,
Therapia Hungarica (English edition),
G Gallasch, and
C Dörfer, and
T Schmitt, and
A Stage
August 2002,
VASA. Zeitschrift fur Gefasskrankheiten,
G Gallasch, and
C Dörfer, and
T Schmitt, and
A Stage
January 2000,
European review for medical and pharmacological sciences,
G Gallasch, and
C Dörfer, and
T Schmitt, and
A Stage
December 2006,
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
G Gallasch, and
C Dörfer, and
T Schmitt, and
A Stage
January 2007,
The British journal of ophthalmology,
G Gallasch, and
C Dörfer, and
T Schmitt, and
A Stage
May 1995,
The British journal of ophthalmology,
G Gallasch, and
C Dörfer, and
T Schmitt, and
A Stage
January 1976,
Current medical research and opinion,
